| ¿µ¹® | deoxyribonucleic acid (DNA) | ÇÑ±Û | µ¥¿Á½Ã¸®º¸ÇÙ»ê |
|---|---|---|---|
| ¼³¸í | ÇÙ»êÀÇ ÀÏÁ¾À¸·Î DNA¶ó°íµµ ÇÑ´Ù. DeoxyribonucleotideÀÇ ÁßÇÕüÀ̸ç À¯ÀüÀÚÀÇ ÈÇÐÀû º»Ã¼ÀÌ´Ù. RNA¹ÙÀÌ·¯½º ÀÌ¿ÜÀÇ ¸ðµç »ý¹°Àº DNA¸¦ À¯ÀüÀÚ·Î Áö´Ï°í ÀÖ´Ù. µð¿Á½Ã¸®º¸´ºÅ¬·¹¿ÀƼµå(deoxyribonucleotide)´Â ¿°±â¿Í ´ç(2'-deoxy-D-ribose)°ú ÀλêÀ¸·Î ÀÌ·ç¾îÁø´Ù. ¿°±â´Â ¾Æµ¥´Ñ(adenine), ±¸¾Æ´Ñ(guanine), Ƽ¹Î(thymine)¹× ½ÃÅä½Å(cytosine)ÀÇ 4°¡ÁöÀ̸ç, À̰ÍÀº ´ç¿¡ ºÎÂøµÇ¾î ÀÖ´Ù. ÀÎ»ê ¿ª½Ã ´çÀÇ ÇÑ ºÎºÐ¿¡ ºÎÂøµÇ¾î ÀÖ´Ù. ÀÌ deoxyribonucleotideÀÇ ´çÀº ´Ù¸¥ deoxy- ribonucleotideÀÇ ´ç°ú ÀλêÀ» »çÀÌ¿¡ ³õ°í °áÇÕÀ» ÇÏ°Ô µÇ¾î ÇϳªÀÇ ±ä »ç½½À» Çü¼ºÇÏ°Ô µÈ´Ù. Áï ´ç°ú ÀλêÀÌ ÁÖÃàÀÌ µÇ¾î¼ deoxyribonucleotideÀÇ ±ä »ç½½À» ¸¸µç´Ù. ÀÌ deoxyribonucleotideÀÇ »ç½½ µÎ °³´Â °¢°¢ deoxyribonucleotide¿¡ ºÎÂøµÇ¾î ÀÖ´Â ¿°±âµéÀÌ °áÇÕÀ» ÇÏ¿© µÎ °³ÀÇ »ç½½ÀÌ °áÇյǾî ÀÖ´Â ÀÌÁß³ª¼± ±¸Á¶¸¦ ¸¸µé°Ô µÈ´Ù. 4°¡Áö ¿°±â ¾Æµ¥´ÑÀº Ƽ¹Î°ú °áÇÕÀ» Çϰí, ½ÃÅä½Å°ú °áÇÕÀ» ÇÏ°Ô µÈ´Ù. Áï ´ç°ú ÀλêÀº ±ä »ç½½À» ¸¸µå´Â ¿ªÇÒÀ» ÇÏ°í ±ä »ç½½¿¡ ºÎÂøµÈ ¿°±âµéÀÇ °áÇÕ¿¡ ÀÇÇØ¼ µÎ °³ÀÇ ±ä »ç½½Àº ¼·Î ºÙ¾î¼ ÀÌÁß³ª¼± ±¸Á¶¸¦ ¸¸µç´Ù. DNAÀÇ À¯ÀüÁ¤º¸´Â ¿°±â¿¡ ÀúÀåµÈ´Ù. 4°³ÀÇ ¿°±âÀÇ Á¶ÇÕ°ú ¹è¿ÀÌ À¯ÀüÁ¤º¸¸¦ º¸°üÇÏ´Â ÇϳªÀÇ ¾ÏÈ£ ¿ªÇÒÀ» ÇàÇÏ°Ô µÈ´Ù. |
||
| ¿µ¹® | retinoic acid | ÇÑ±Û | ·¹Æ¼³ë»ê |
|---|---|---|---|
| ¼³¸í | C20H28O2. ºñŸ¹Î AÀÇ ¾ËÄڿñ⸦ ¾Ëµ¥È÷µå·Î »êÈÇÑ ÈÄ ´Ù½Ã Ä«¸£º¹½Ç»êÀ¸·Î »êÈÇÏ¿© ¾òÀº »ê. ¹ß»ýÁßÀÇ ¼¼Æ÷¿¡ ÀÛ¿ëÇÏ¿© ÇüŸ¦ ¸¸µå´Âµ¥ °ü¿©ÇÑ´Ù. |
||
| ¿µ¹® | ribonucleic acid | ÇÑ±Û | ¸®º¸ÇÙ»ê |
|---|---|---|---|
| ¼³¸í | Ribonucleotide monomer·Î ÀÌ·ç¾îÁø ÇÙ»êÀ¸·Î ¿°±â, ´ç, ÀλêÀ¸·Î ±¸¼ºµÈ´Ù. ¿°±â´Â adenine, guanine, cytosine, uracilÀÇ 4Á¾·ù°¡ ÀÖÀ¸¸ç, ´çÀº 5ź´çÀÌ´Ù. RNA´Â DNA¸¦ ÁÖÇüÀ¸·Î ÇÏ¿© »óº¸ÀûÀ¸·Î °áÇÕ, Çü¼ºµÇ¸ç ´Ü¹éÁúÀ» ¸¸µé¾î³»´Â µ¥¿¡ ÀÖ¾î Áß¿äÇÑ ¿ªÇÒÀ» ÇÑ´Ù. Àü·É RNA(mRNA)´Â ´Ü¹éÁú ÇÕ¼º¿¡ ÀÖ¾î °¡Àå ±âº»ÀÌ µÇ´Â DNAÀÇ ¼¿À» »óº¸ÀûÀ¸·Î ¿Å°Ü ¹Þ¾Æ Àü´ÞÇÏ´Â Àü·É±¸½ÇÀ» ÇÏ´Â RNA. ¸®º¸¼Ø RNA(rRNA) ¸®º¸¼ØÀ» Çü¼ºÇÏ´Â 4°¡Áö RNA»ç½½(28S, 18S, 5.8S, 5S·Î ±¸¼º). Àü´Þ RNA(tRNA) ƯÁ¤ ¾Æ¹Ì³ë»êÀ» ÇÑÂÊ ³¡¿¡ Áö´Ï°í »óº¸Àû ¼¿ÀÇ mRNA¿Í ÀϽÃÀû °áÇÕÀ» ÀÌ·ç¸ç ´Ü¹éÁú ÇÕ¼º¿¡ Á÷Á¢ ±â¿©ÇÏ´Â RNAÀÌ´Ù. |
||
| ¿µ¹® | acid | ÇÑ±Û | »ê |
|---|---|---|---|
| ¼³¸í | ¹°¿¡ ³ì¾ÒÀ» ¶§ ÀÌ¿ÂÈÇÏ¿© ¼ö¼Ò ÀÌ¿ÂÀ» ¸¸µå´Â ¹°Áú. ½Å¸ÀÀÌ ³ª°í û»ö ¸®Æ®¸Ó½º Á¾À̸¦ ºÓ°Ô º¯È½ÃŰ¸ç ¿°±â¿ÍÀÇ ÁßÈ ¹ÝÀÀ¿¡ ÀÇÇÏ¿© ¹°°ú ¿°À» ¸¸µé°í ÀÌ¿ÂÈ ¿¿¡¼ ¼ö¼Òº¸´Ù ¾Õ¿¡ ÀÖ´Â ±Ý¼Ó°ú ¹ÝÀÀÇÏ¿© ¿°À» ¸¸µé¸é¼ ¼ö¼Ò¸¦ ¹ß»ý½ÃŲ´Ù. ¼ö¼Ò ¿øÀÚ¸¦ ÀÌ¿ÂÈÇÏ´Â ÈûÀÇ °¾à¿¡ µû¶ó °»ê°ú ¾à»êÀ¸·Î ³ª´¶´Ù. |
||
| ¿µ¹® | acetic acid | ÇÑ±Û | ¾Æ¼¼Æ®»ê, ÃÊ»ê |
|---|---|---|---|
| ¼³¸í | ºÐÀÚ½ÄÀº C2H4O2, ºÐÀÚ·® 60.05ÀÇ Àú±Þ Áö¹æ»êÀÌ´Ù. CH3COOHÀÇ ±¸Á¶½ÄÀ» °¡Áø ¹«»ö¾×ü·Î 16.7¡É¿¡¼ ³ì°í 118.0¡É¿¡¼ ²ú´Â´Ù. ½ÄÃÊÀÇ ½Å¸ÀÀ» ³»´Â °ÍÀ̰í, ³óÃàµÈ °ÍÀ» ºùÃÊ»êÀ̶ó ÇÑ´Ù. »ó¿Â¿¡¼´Â ¾×üÀÌ¸ç ¼ö¿ë¾×Àº ¾à»ê¼ºÀÌ´Ù. »ýü³»¿¡¼´Â ÀϹÝÀûÀ¸·Î ¾Æ¼¼Æ¿ CoA·Î Á¸ÀçÇÏ¸ç ¾Æ¼¼Æ¿±âÀÇ °ø±Þ¿øÀÌ µÇ´Â ¿Ü¿¡ Áö¹æ»êÀ̳ª ½ºÅ×·ÎÀÌµå µîÀÇ »ý¼ºÀç·á·Î Áß¿äÇÏ´Ù. ¾Æ¼¼Æ¿ CoA·ÎºÎÅÍ´Â ÄÉÅæÃ¼°¡ ÇÕ¼ºµÇ¸ç Á¶Á÷ÀÇ ¿¡³ÊÁö¿øÀÌ µÈ´Ù. |
||
| NA | Avogadro constant or number; nalidixic acid; Narcotics Anonymous; network administrator; neuraminida... |
|---|---|
| NAA | N-acetyl aspartate; naphthaleneacetic acid; neutral amino acid; neutron activation analysis; neutrop... |
| CAN'T | LEAP cyclosporine, alcohol, nicotinic acid, thiazides, lasix, ethambutanol, aspirin, pyrazinamide [s... |
| NAD | neutrophil actin dysfunction; new antigenic determinant; nicotinamide adenine dinucleotide; nicotini... |
| NAMN | nicotinic acid mononucleotide |
| ARM | Age-related maculopathy |
|---|---|
| NA | Nicotinic acid |
| niacin | Nicotinic acid |
| NAADP | Nicotinic acid adenine dinucleotide phosphate |
| nAChR | Nicotinic ACh receptor |
| nicotinic acid maculopathy | Maculopathy observed in persons taking 3000 mg or more of nicotinic acid daily; normal vision returns after this medication is discontinued. (05 Mar 2000) |
|---|
| nicotinic acid | A precursor of NAD, that is a product of the oxidation of nicotine. (18 Nov 1997) |
|---|---|
| nicotinic acid amide | <biochemistry> Member of the water soluble B vitamin group, used in the production of fatty acids, steroids and cholesterol, deficiency is known as pellagra. Has cholesterol-lowering and vasodilating properties. (27 Sep 1997) |
| bull's-eye maculopathy | An ocular condition in which oedema or degeneration of the sensory retina at the posterior pole of the eye causes alternating areas of light and dark, as in a target; seen in toxic, inflammatory, and hereditary conditions. (05 Mar 2000) |
| maculopathy | Any pathological condition of the macula lutea. Synonym: macular retinopathy. (05 Mar 2000) |
| cystoid maculopathy | Cystic degeneration of the central retina that may occur after cataract extraction, in senile macular degeneration, and in other retinal abnormalities. (05 Mar 2000) |
| solar maculopathy | Damage to the fovea centralis of the retina and the adjacent choroid due to the thermal action of infrared rays, consequent to sungazing or watching a solar eclipse without sufficient eye protection. See: photoretinopathy. Synonym: eclipse blindness, solar blindness. (05 Mar 2000) |
| familial pseudoinflammatory maculopathy | Familial macular degeneration resembling inflammatory changes. (05 Mar 2000) |
| receptors, nicotinic | One of the two major classes of cholinergic receptors. Nicotinic receptors were originally distinguished by their preference for nicotine over muscarine. They are generally divided into muscle-type and neuronal-type (previously ganglionic) based on pharmacology, molecular biology, and biophysical properties of the channels. (12 Dec 1998) |
| nicotinic | <chemistry> Pertaining to, or derived from, nicotine; nicotic; used specifically to designate an acid related to pyridine, obtained by the oxidation of nicotine, and called nicotinic acid. Source: Websters Dictionary (01 Mar 1998) |
| nicotinic acetylcholine receptor | Integral membrane protein of the postsynaptic membrane to which acetylcholine binds. The receptor contains an integral ion channel, as a result of binding of acetylcholine, ion channels in the subsynaptic membrane are opened. at the neuromuscular junction, the nicotinic acetylcholine receptor initiates muscle contraction. Currently the best characterised ion channel protein: made of a hetero pentamer of related subunits, although a homo pentamer is functional in insects. Structural studies show that the acetylcholine binding site and the ionic channel are part of the same macromolecular unit. The nAChR mediates rapid transduction events (1ms) whereas receptors activating G-protein coupled channels operate on slower time scales (millisecond to second range). (18 Nov 1997) |
| nicotinic acids | 2-, 3-, or 4-pyridinecarboxylic acids. Pyridine derivatives substituted with a carboxy group at the 2-, 3-, or 4-position. The 3-carboxy derivative (niacin) is active as a vitamin. (12 Dec 1998) |
| nicotinic agonists | Drugs that bind to and activate nicotinic cholinergic receptors (receptors, nicotinic). Nicotinic agonists act at postganglionic nicotinic receptors, at neuroeffector junctions in the peripheral nervous system, and at nicotinic receptors in the central nervous system. Agents that function as neuromuscular depolarising blocking agents are included here because they activate nicotinic receptors, although they are used clinically to block nicotinic transmission. (12 Dec 1998) |
| nicotinic alcohol | <chemical> 3-pyridinemethanol. A direct-acting peripheral vasodilator that causes flushing and may decrease blood pressure. It is used in vasospasm and threatened gangrene. Pharmacological action: vasodilator agents. Chemical name: 3-Pyridinemethanol (12 Dec 1998) |
| nicotinic antagonists | Drugs that bind to nicotinic cholinergic receptors (receptors, nicotinic) and block the actions of acetylcholine or cholinergic agonists. Nicotinic antagonists block synaptic transmission at autonomic ganglia, the skeletal neuromuscular junction, and at central nervous system nicotinic synapses. (12 Dec 1998) |
| nicotinic cholinergic receptor | A class of receptors responsive to acetylcholine that also are activated by nicotine; ganglionic (including the adrenal medulla) and neuromuscular receptors. Two classes exist: nicotinic-neuronal and nicotinic-muscular. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|